SCHEMBL25907173

SCHEMBL25907173

CCc1cc(O)c2cccnc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.43
PDPK1 O15530 1/20 0.41
COMT P21964 2/20 0.40
KDM4E B2RXH2 5/20 0.39
NPC1 O15118 4/20 0.39
L3MBTL1 Q9Y468 4/20 0.39
BRD4 O60885 2/20 0.39
MITF O75030 1/20 0.39
HTT P42858 3/20 0.39
SLC6A2 P23975 1/20 0.39
RAB9A P51151 3/20 0.38
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALOX12 P18054 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
DHODH Q02127 1/20 0.35
FAAH O00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25082354 0.81 CCR1 (0.47) IDO1PDPK1KDM4ENPC1L3MBTL1
SCHEMBL13968415 0.79 HTT (0.44) IDO1COMTKDM4ENPC1L3MBTL1
SCHEMBL2302448 0.78 NPC1 (0.40) IDO1COMTKDM4ENPC1L3MBTL1
SCHEMBL12426313 0.75 KDM4E (0.44) IDO1COMTKDM4ENPC1L3MBTL1
SCHEMBL2018134 0.75 CYP1A2 (0.35) IDO1KDM4ELMNATSHR
SCHEMBL4048229 0.75 POLB (0.48) KDM4ENPC1L3MBTL1HTTGAA
SCHEMBL12424719 0.71 CCR1 (0.47) KDM4ENPC1L3MBTL1HTTRAB9A
SCHEMBL12424718 0.70 CCR1 (0.47) IDO1HTTSLC6A2DHODHMETAP2
SCHEMBL3904763 0.69 DAO (0.39) COMTKDM4ENPC1L3MBTL1RAB9A
SCHEMBL277431 0.69 KDM4E (0.44) IDO1COMTKDM4ENPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242524-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242524-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV IDO1 4361/4885PDPK1 2305/4885COMT 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.